Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

December 1, 2024

Study Completion Date

March 25, 2025

Conditions
Myelodysplastic SyndromesHodgkin's LymphomaNon-Hodgkin's LymphomaAcute LeukemiaMultiple Myeloma
Interventions
BIOLOGICAL

Rituximab

Rituximab: 375 mg/m\^2 intravenous (IV) day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.

DRUG

Conditioning chemotherapy

Fludarabine:30 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m\^2 per day IV infusion over 2 hours on Days 6, -5, -4, -3. Mesna: 1200 mg/m\^2 per day IV infusion, daily on days 6, -5, -4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3.

DRUG

TMS

Tacrolimus: 0.02 mg/kg, start day 3. Continue intravenous (IV) or by mouth (PO). Taper will begin at day +60 if no acute graft-versus-host disease (GVHD) then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m\^2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.

DRUG

FLAG

Fludarabine: 25 mg/m\^2 per day intravenous (IV) over 30 minutes, daily on days 1-5 Cytarabine: 2,000 mg/m\^2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy.

DRUG

EPOCH-F

"Fludarabine: 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days 1-4. Etoposide: 50 mg/m\^2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin: 10 mg/m\^2/day continuous intravenous (CIV), days 1-4. Vincristine: 0.4 mg/m\^2 per day continuous IV infusion over 24 hours daily on days 1-4.~Cyclophosphamide: 750 mg/m\^2 IV infusion over 30 minutes on day 5. Prednisone: 60 mg/m\^2 per day by mouth (PO) daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV."

PROCEDURE

Hematopoietic stem cell transplant

Hematopoietic stem cell transplant

DRUG

Palifermin

Escalating doses of palifermin given during transplant phase.

DRUG

Acetaminophen

Before each infusion of rituximab as indicated.

DRUG

Diphenhydramine

Before each infusion of rituximab as indicated.

DRUG

Prednisone

For engraftment syndrome.

DRUG

Epinephrine

Emergency medication as indicated.

OTHER

IV Saline

Before each infusion of rituximab as indicated.

DIAGNOSTIC_TEST

ECG

As indicated.

DIAGNOSTIC_TEST

ECHO

As indicated.

DIAGNOSTIC_TEST

MUGA

As indicated.

DIAGNOSTIC_TEST

DEXA

As indicated.

DIAGNOSTIC_TEST

CT chest

As indicated.

DIAGNOSTIC_TEST

PET

As indicated.

DIAGNOSTIC_TEST

MRI

As indicated.

PROCEDURE

BM aspirate

As indicated.

PROCEDURE

BM biopsy

As indicated.

PROCEDURE

Lumbar puncture

As indicated.

Trial Locations (2)

20892

National Institutes of Health Clinical Center, Bethesda

55401

National Marrow Donor Program, Minneapolis

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter